Docetaxel/doxorubicin/gemcitabine

  • PDF / 169,027 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 92 Downloads / 184 Views

DOWNLOAD

REPORT

1 S

Lack of efficacy: case report A patient [age and sex not stated] experienced lack of efficacy during treatment with doxorubicin, gemcitabine and docetaxel for metastatic malignant phyllodes tumour. The patient, who was diagnosed with malignant phyllodes tumour with involvement of the chest wall and lungs, started receiving conventional chemotherapies comprising doxorubicin, gemcitabine and docetaxel [routes and dosages not stated]; however, the patient showed primary resistance (lack of efficacy) to the conventional chemotherapies. Consequently, the patient received off-label therapy with pazopanib and achieved a partial response. Ng DYX, et al. 57P Therapeutic vulnerability of malignant phyllodes tumour to pazopanib identified through a novel patient-derived xenograft and cell line model. Annals of 803520413 Oncology 31 (Suppl. 6): S1264 abstr. 57P, Nov 2020. Available from: URL: http://doi.org/10.1016/j.annonc.2020.10.077 [abstract]

0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 12 Dec 2020 No. 1834

Data Loading...